Generex Biotechnology Co. (OTCMKTS:GNBT) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.95 and traded as high as $2.04. Generex Biotechnology shares last traded at $2.04, with a volume of 7,461 shares changing hands.
Separately, ValuEngine downgraded shares of Generex Biotechnology from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd.
The stock’s 50 day simple moving average is $2.29 and its two-hundred day simple moving average is $1.96.
Generex Biotechnology Company Profile (OTCMKTS:GNBT)
Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity.
Featured Article: What is the market perform rating?
Receive News & Ratings for Generex Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generex Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.